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18 ABSTRACT
19 Endogenous glucocorticoid action is important in the structural and functional maturation of 
20 the fetal heart. In fetal mice, although glucocorticoid concentrations are extremely low 
21 before E14.5, glucocorticoid receptor (GR) is expressed in the heart from E10.5. To 
22 investigate whether activation of cardiac GR prior to E14.5 induces precocious fetal heart 
23 maturation, we administered dexamethasone in the drinking water of pregnant dams from 
24 E12.5-E15.5. To test direct effects of glucocorticoids upon the cardiovascular system we 
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225 used SMGRKO mice, with Sm22-Cre-mediated disruption of GR in cardiomyocytes and 
26 vascular smooth muscle. Contrary to expectations, echocardiography showed no 
27 advancement of functional maturation of the fetal heart. Moreover, litter size was 
28 decreased 2 days following cessation of antenatal glucocorticoid exposure, irrespective of 
29 fetal genotype. The myocardial performance index and E/A wave ratio, markers of fetal 
30 heart maturation, were not significantly affected by dexamethasone treatment in either 
31 genotype. Dexamethasone treatment transiently decreased the myocardial deceleration 
32 index (MDI; a marker of diastolic function), in control fetuses at E15.5, with recovery by 
33 E17.5, 2 days after cessation of treatment. MDI was lower in SMGRKO than in control 
34 fetuses and was unaffected by dexamethasone. The transient decrease in MDI was 
35 associated with repression of cardiac GR in control fetuses following dexamethasone 
36 treatment. Measurement of glucocorticoid levels in fetal tissue and hypothalamic 
37 corticotropin-releasing hormone (Crh) mRNA levels suggest complex and differential effects 
38 of dexamethasone treatment upon the hypothalamic-pituitary-adrenal axis between 
39 genotypes. These data suggest potentially detrimental and direct effects of antenatal 
40 glucocorticoid treatment upon fetal heart function.  
41
42
43 INTRODUCTION
44 Levels of glucocorticoid hormones rise markedly shortly prior to birth, to promote fetal 
45 organ and tissue maturation in preparation for birth and subsequent postnatal life (Fowden 
46 et al., 1998). This is mimicked with the administration of potent synthetic glucocorticoids 
47 (betamethasone or dexamethasone) to pregnant women at risk of preterm delivery, in 
48 order to mature fetal organs, thereby reducing neonatal morbidity and mortality should 
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349 preterm birth ensue (Roberts et al., 2017, Agnew et al., 2018). A great deal is known about 
50 the maturational effects that endogenous as well as exogenous glucocorticoids have on the 
51 lungs (Bird et al., 2015, Roberts et al., 2017). However, the role of glucocorticoids in the 
52 maturation of other fetal organs has not been well characterised and concerns have been 
53 raised that non-optimal antental glucocorticoid therapy might increase adverse outcomes, 
54 including perinatal death (reviewed, Kemp et al., 2017). The effects of endogenous 
55 glucocorticoids upon fetal heart maturation were, until recently, unclear. We demonstrated 
56 an important role for endogenous glucocorticoids, acting via the glucocorticoid receptor 
57 (GR), in fetal heart maturation. At embryonic day (E) 17.5, global GR knock-out mice show 
58 impaired heart structure and function and fail to show the normal maturational changes in 
59 late gestation cardiac expression of genes involved in contractile function, calcium handling 
60 and energy metabolism (Rog-Zielinska et al., 2013). Tissue-specific knock-out of GR by 
61 smooth muscle protein 22 (SM22)-Cre-driven recombination showed that most of these 
62 maturational effects are attributable to direct actions of GR within cardiomyocytes and/or 
63 vascular smooth muscle cells (VSMC) (Rog-Zielinska et al., 2013). Expression profiling and in 
64 silico transcription factor analysis in sheep heart suggest that endogenous glucocorticoids 
65 similarly promote the metabolic transitions that occur close to birth in large animals 
66 (Richards et al., 2015). In contrast, although a number of animal studies have investigated 
67 the effects of fetal exposure to exogenous glucocorticoids upon subsequent heart structure 
68 and function in adulthood (termed “fetal programming” (Agnew et al., 2018, Rog-Zielinska 
69 et al., 2014)), few have examined the impact of exogenous glucocorticoid administration 
70 upon the heart in utero, likely to underpin the long-term effects. Studies in fetal sheep 
71 hearts have shown that late gestation maternal hypercortisolemia impacts the myocyte 
72 transcriptome, with some changes indicative of precocious maturation, but others not 
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473 (Richards et al., 2014). However, whether these effects are mediated by alterations in 
74 maternal or placental physiology, or reflect direct actions upon fetal cardiomyocytes is 
75 unknown. A clear consensus regarding the direct impact of exogenous glucocorticoid upon 
76 the fetal heart has yet to emerge. 
77
78 Here, we hypothesised that early activation of GR would advance fetal heart maturation and 
79 that this would be via direct activation of GR in fetal cardiomyocytes. We tested our 
80 hypothesis by administering antenatal dexamethasone in mice, from E12.5 to E15.5 (prior to 
81 the natural late gestation peak in endogenous glucocorticoid levels at E16.5 to E17.5). To 
82 assess the direct involvement of GR in cardiomyocytes we used SMGRKO mice, with SM22-
83 Cre-driven deletion of GR in cardiomyocytes and VSMC. The effect on heart function in utero 
84 was investigated at E15.5 and at E17.5, during and 2 days following cessation of treatment, 
85 respectively. Parameters of glucocorticoid action were investigated ex vivo, including GR 
86 (Nr3c1) and GR target genes (Fkbp5, Kcnj12) as well as markers of cardiac maturation - 
87 genes encoding calcium handling proteins that are indirectly regulated by GR in heart (Rog-
88 Zielinska et al., 2015). 
89
90 MATERIALS AND METHODS
91 Animals
92 All animal experiments were approved by the University of Edinburgh Animal Welfare and 
93 Ethical Review Body and were carried out in strict accordance with accepted standards of 
94 humane animal care under the auspices of the Animal (Scientific Procedures) Act UK 1986. 
95 SMGRKO mice (on a C57Bl/6 genetic background) have been previously described (Rog-
96 Zielinska et al., 2013). They carry a deletion of exon 3 of the Nr3c1 gene (encoding GR) in 
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597 cardiomyocytes and vascular smooth muscle, the result of Sm22-Cre mediated 
98 recombination of a ‘floxed’ GR allele (GRfl/fl). Experimental SMGRKO fetuses and control 
99 littermates were generated by mating male SMGRKO (GRfl/fl Sm22-Cre+) mice with control 
100 females (GRfl/fl Sm22-Cre-). The morning of the day the vaginal plug was found was 
101 designated E0.5. Singly housed pregnant females received either dexamethasone 
102 (100μg/kg/d, dose calculated based on daily weight and water intake measurements per 
103 mouse)(Sigma-Aldrich, St Louis, USA) or vehicle (EtOH, approx 0.023% depending on body 
104 weight and water consumption) in their drinking water from E12.5 to E15.5. Cre genotyping 
105 was carried out on tissue biopsies using primers: 5′-GATCGCTGCCAGGATATACG-3′ and 5′-
106 AGGCCAGGTATCTCTGACCA-3′. Fetuses were weighed then killed by decapitation at either 
107 E15.5 or E17.5. Fetal heads were rapidly frozen on dry ice for in situ mRNA hybridisation. For 
108 RNA extraction, fetal hearts were dissected, weighed and rapidly frozen on dry ice. For 
109 liquid chromatography mass-spectrometry (LC-MS/MS), fetal and maternal livers were 
110 dissected, weighed and rapidly frozen on dry ice. Tissues were stored at -80°C prior to 
111 extraction and analysis. 
112
113 High-resolution ultrasound analysis
114 Fetal cardiac function was assessed at E15.5 or E17.5 using a Visualsonics Vevo 770 High 
115 Resolution Ultrasound Scanner. Briefly, pregnant mice were anaesthetised with 2% 
116 isoflurane gas, laid supine with all limbs taped to electrocardiogram electrodes to monitor 
117 heart rate (~450bpm) and body temperature maintained at 37°C. Fetuses were counted for 
118 identification purposes and all were scanned. Abdominal hair was removed using a 
119 commercially available depilating cream, then pre-warmed ultrasound gel (Aquasonic 100; 
120 Parker Laboratories, Orange, NJ, USA) was applied. A 30 MHz RMV 707B (real-time 
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6121 microvisualization) transducer was used, with a focal length of 12.7mm and a depth of field 
122 view of 20mm. Pulse-wave Doppler was used to measure blood flow across the mitral valve 
123 using the apical four chamber view. Vevo 770 image analysis software was used to measure 
124 and analyse B-mode images and Doppler waveform traces. Following imaging, the dam was 
125 killed by cervical dislocation. Scanned fetuses were excised following identification by 
126 validation of position from the scanned images, then weighed, decapitated and tissues 
127 collected. 
128
129 RNA analysis
130 RNA was extracted from fetal hearts by homogenisation in TRIzol (Thermo Fisher Scientific) 
131 followed by purification using a Purelink RNA mini kit (Thermo Fisher Scientific). cDNA was 
132 synthesised using a QuantiTect Reverse Transcription Kit (Qiagen) then subject to 
133 quantitative (q)PCR (in triplicate) using the Roche Lightcycler 480 system with gene-specific 
134 primer sets and Universal Probe Library (Roche) (Supplementary Table 1). A standard curve 
135 was prepared from pooled cDNA samples. Relative quantification was provided by 
136 LightCycler software using the maximum second derivative method. mRNA levels are 
137 expressed relative to a combination of the mean of 2 or more of 18s, Actb, Hprt and Tbp 
138 mRNA levels, used as internal standards (as detailed in the figure legends).
139
140 In situ mRNA hybridisation
141 Coronal sections (10µm) of fetal heads were cut using a cryostat, collected onto Polysine® 
142 slides and stored at −75°C until processing. Corticotropin-releasing hormone (Crh) mRNA 
143 was measured using a 35S-UTP radio-labelled cRNA probe used extensively by ourselves and 
144 others (Welberg et al., 2000, Brunton et al., 2015, Grundwald and Brunton, 2015, Harris et 
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7145 al., 2001) under conditions optimised in our laboratory. Briefly, 35S-cRNA was synthesized 
146 from a linearized pBluescript vector expressing a 518bp Crh cDNA fragment (a gift from Dr. 
147 Robert Thompson, University of Michigan, Ann Arbor, MI, USA). The plasmid was linearized 
148 with HindIII or XbaI and transcribed from the T7 or T3 promoters, respectively to synthesize 
149 the sense and antisense probes. ISH was performed as previously described (Brunton et al., 
150 2009), except that following the RNase A step, slides were washed 3 x 50 minutes in 0.1 x 
151 SSC at 60°C. Following the post-hybridization washes, sections were dehydrated in an 
152 ascending series of ethanol containing 300mM ammonium acetate, air-dried and then 
153 exposed to autoradiographic film (Amersham Hyperfilm MP, GE Healthcare, 
154 Buckinghamshire, UK) at room temperature. Films were developed (Ilford Phenisol) and 
155 fixed (Ilford Hypam fixer). To optimise exposure times for autoradiographic film, a trial set of 
156 slides were exposed to film and developed at 2 day intervals until the exposure time which 
157 produced the best signal to noise ratio was identified and this exposure time (6 days) was 
158 used for the experimental tissue. Slides were subsequently dipped in autoradiographic 
159 emulsion and exposed at 4oC for 5 weeks then developed, counterstained with 
160 haematoxylin and eosin and viewed under a light microscope to confirm neuroanatomical 
161 localisation of the PVN. CRH mRNA expression in the paraventricular nucleus (PVN) of the 
162 hypothalamus was examined bilaterally in 3-6 sections/mouse with measurements taken 
163 from the mid-section on which CRH was apparent. Semiquantitative densitometric analysis 
164 of autoradiographic films using ImageJ software was used to calculate mean grey density. 
165 Sections hybridized with sense probes served as negative controls and showed no signal 
166 above background.
167
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8168 Western Blot
169 Protein was extracted from fetal heart tissue by homogenising in RIPA lysis and extraction 
170 buffer, followed by protein quantification using a Pierce BCA assay (both Thermo Fisher 
171 Scientific). Samples (20μg protein) were added to NuPAGE Sample Reducing Buffer and 
172 NuPAGE LDS Sample Buffer (both Thermo Fisher Scientific), and denatured at 70°C for 10 
173 minutes prior to electrophoresis on a NuPAGE Novex 4–12% Bis Tris gel in NuPAGE MES SDS 
174 running buffer (Thermo Fisher Scientific). Following protein transfer to a nitrocellulose 
175 membrane, non-specific binding was blocked by incubation in 5% blotting-grade blocker 
176 (BioRad) in TBS-T for 1 hour. Membranes were incubated with primary antibodies: GR 
177 (1:400; G-5: sc-393232, Santa Cruz) and β-tubulin (1:1000; MAB3408, Merck MilliPore) 
178 overnight at 4°C. Membranes were then washed and incubated with secondary antibodies 
179 IRDye 800CW Goat anti-mouse IgG (1:10000; 926-32210, Licor Biosciences) and IRDye® 
180 680RD Goat anti-Mouse IgG (1:10000; 925-68070, Licor Biosciences), followed by 
181 quantification of GR protein levels relative to β-tubulin using an Odyssey infrared imaging 
182 system (Licor Biosciences).
183
184 Liquid chromatography-mass spectrometry (LC-MS/MS)
185 Livers were pooled from all fetuses from a litter to accumulate a weight of approximately 
186 100mg tissue (1 sample per litter). Tissues were homogenised in 3ml methanol:water (7:2, 
187 v/v) and enriched with 5ng internal standard solution (Epi-corticosterone d4-
188 dexamethasone, d4-cortisol) added to each sample. Homogenates were shaken then 
189 centrifuged at 3200g for 45 minutes at 4°C before collecting the supernatant and reducing 
190 to dryness using oxygen-free nitrogen at 60°C. For simultaneous quantification of 
191 dexamethasone, 6-hydroxydexamethasone, 11-dehydrodexamethasone, corticosterone and 
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9192 11-dehydrocorticosterone, calibration standards (1mg/ml) of each steroid were diluted to 
193 10µg/mL stock in methanol to generate a calibration curve (range, 0.0001-50ng, geometric 
194 progressions of 25) enriched with 5ng internal standard solution (Epi-corticosterone d4-
195 dexamethasone, d4-cortisol) and reduced to dryness under oxygen-free nitrogen. Samples 
196 and calibration standards were resuspended in 2ml 20% methanol and transferred to Classic 
197 Sep-pak columns (2mg, Waters®, Borehamwood, UK) that had been primed with methanol 
198 (2ml) and water (2ml) before sample loading. Sep Paks were washed with 2ml water and 
199 steroids were eluted with 2ml 100% methanol and collected into a glass vial, before 
200 reducing to dryness under oxygen-free nitrogen at 60°C. Samples were resuspended in 
201 100µl 70:30 water/acetonitrile for LC-MS/MS analysis.
202
203 Samples were injected (20µl) onto a C18-AR column (ACE Excel 150 x 2.1mm; 2µm, ACT 
204 Technologies, Aberdeen, UK) at 40°C using a flow rate of 0.5ml/min, mobile phase A – water 
205 0.1% formic acid, B- acetonitrile 0.1% formic acid from 20-90% B over 10 minutes, protected 
206 by a Kinetex KrudKatcher® (Phenomenex, Macclesfield, UK), followed by analysis on a 
207 QTrap® 5500 LC-MS/MS System (Sciex) or QTrap 6500 Triple Quadrupole, Mass 
208 Spectometer (Sciex) system. 
209
210 The peak areas of each steroid and each internal standard were integrated using 
211 MultiQuant™ version 3.0.8 software (Version number 3.0.8664.0 2015 AB SCIEX with 
212 Scheduled MRM™ Algorithm support) (Sciex, 2015). Linear regression analysis of calibration 
213 standards, calculated using peak area ratios of steroid of interest to internal standard, was 
214 used to determine the concentration of the steroid of interest in the samples. R2>0.99 was 
215 considered acceptable and within each batch of samples the accuracy at the upper and 
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216 lower limits were only accepted if accuracy <20%. The amount of steroid was calculated 
217 using linear regression analysis of the peak area ratio and was expressed as ng of analyte 
218 per g liver. 
219
220 Statistical analysis
221 All numerical data are presented as means ± SEM, with p<0.05 deemed significant. 
222 GraphPad Prism 6 software was used for statistical analysis, with unpaired Student’s t-test 
223 and two-way ANOVA with post-hoc Tukey or Bonferroni tests, as appropriate. All data were 
224 subject to Shapiro-Wilk normality testing prior to further analysis. 
225
226 RESULTS
227 Dexamethasone treatment reduced fetal number at E17.5, irrespective of genotype with 
228 no effect on heart weight. Body weight was increased in SMGRKO mice at E17.5.
229 Dexamethasone treatment from E12.5 to E15.5 had no effect on litter size at E15.5 (Figure 
230 1A). We noted that, irrespective of treatment, E15.5 litters contained more SMGRKO than 
231 control fetuses (Figure 1B). There was no effect of dexamethasone on fetal weight at E15.5, 
232 nor did this differ between genotypes (Table 1), and there was no association between fetal 
233 weight and litter size (Supplementary Figure 1A). Heart weight at E15.5 was unaffected by 
234 dexamethasone treatment and was similar between control and SMGRKO mice (Table 1). In 
235 contrast, 2 days after cessation of dexamethasone treatment, at E17.5, litter size was 
236 reduced (Figure 1C). Both genotypes were affected (Figure 1D), suggesting the decrease in 
237 litter size is not due to a direct effect of dexamethasone on the fetal heart via GR. Fetal 
238 weight did not show any relationship to litter size at E17.5 (Supplementary Figure 1B), nor 
239 did we see any direct evidence for an increase in fetal deaths at E17.5 (2 dead/resorbed 
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240 fetuses across all 24 litters at E17.5, versus 4 across 24 litters at E15.5). However, at E17.5, 
241 dexamethasone treated SMGRKO fetuses weighed more than littermate controls and were 
242 also heavier than vehicle treated SMGRKO fetuses (Table 1). This is suggestive of oedema in 
243 SMGRKO fetuses, as previously identified (Rog-Zielinska et al., 2013), 2 days following 
244 cessation of dexamethasone treatment, however, this requires experimental confirmation. 
245 There were no differences in fetal heart weights between genotypes or treatment groups at 
246 E17.5 (Table 1).
247
248 Dexamethasone treatment transiently altered cardiac diastolic function at E15.5 in a GR-
249 dependent manner, with no effect on systolic function. 
250 Fetal adrenal glucocorticoid synthesis in mice initiates at E14.5 and peaks around E17.5 
251 (Michelsohn and Anderson, 1992). To investigate whether antenatal dexamethasone 
252 treatment prior to this can advance the maturation of fetal heart function, 
253 echocardiography was performed at E15.5 (end of treatment) or at E17.5 (2 days after 
254 cessation of treatment). Heart rate was not significantly affected by genotype or treatment 
255 at either time point and was in the normal range for these gestational ages (Supplementary 
256 Table 2)(Corrigan et al., 2010). There was no difference in the Doppler-derived myocardial 
257 performance index (MPI; a measure of combined systolic and diastolic function) between 
258 genotypes at either E15.5 or E17.5, nor was it altered by dexamethasone at either time 
259 point. There were also no effects of dexamethasone on any of the components of MPI 
260 (IVCT, IVRT, ET), although the IVRT showed the expected maturational decrease between 
261 E15.5 and E17.5, irrespective of dexamethasone treatment (Supplementary Table 2). The 
262 Doppler-derived E/A wave ratio (the ratio of peak blood flow velocity in early ‘passive’ 
263 diastole to peak velocity in late ‘active’ diastole) was also unaffected by dexamethasone 
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264 treatment, nor did it differ between genotypes (Supplementary Table 2). However, at E15.5, 
265 compared to control mice, SMGRKO mice showed a lower mitral deceleration index (MDI), 
266 calculated by normalising the early filling deceleration time (DT) for peak E wave velocity. 
267 This suggests altered diastolic heart function. Moreover, whilst the MDI of SMGRKO fetuses 
268 was unaffected following dexamethasone treatment, dexamethasone decreased the MDI in 
269 control mice to a level similar to that of SMGRKO mice (Figure 2A), suggesting MDI is 
270 responsive to GR activation in cardiomyocytes/VSMC. By E17.5, the MDI of dexamethasone 
271 treated control fetuses had recovered to the same level as in vehicle treated controls, 
272 although the reduction in the MDI in SMGRKO mice compared to controls persisted (Figure 
273 2B). 
274
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275 Calcium-handling genes, markers of fetal heart maturation, are down-regulated by 
276 dexamethasone treatment.
277 In their report of the application of high-frequency ultrasound to assess the maturation of 
278 the mouse fetal heart, Corrigan et al failed to detect a change in MPI between E16.5 and 
279 E18.5 (Corrigan et al., 2010, Rog-Zielinska et al., 2013), suggesting that MPI alone might not 
280 be a reliable marker of heart maturation. We therefore examined expression of genes 
281 involved in calcium handling that normally increase during fetal heart maturation and which 
282 are indirectly induced by GR in fetal cardiomyocytes (Rog-Zielinska et al., 2015). At E15.5, 2-
283 way ANOVA showed a significant effect of dexamethasone in reducing cardiac expression of 
284 Atp2a2, Cacna1c and Slc8a1 (encoding SERCA2a, Cav1.2 and NCX1, respectively); Ryr2 was 
285 unaffected (Supplementary Figure 2A). By E17.5, expression had recovered in 
286 dexamethasone-exposed fetuses, with Cacna1c even increased in dexamethasone-exposed 
287 control fetuses (Supplementary Figure 2B). Overall, these findings are not consistent with an 
288 advancement in fetal heart maturation and moreover, suggest that dexamethasone may 
289 transiently impair fetal heart function by reducing capacity for calcium handling. This 
290 occurred in both genotypes and is therefore independent of GR expression in 
291 cardiomyocytes/VSMC.
292
293 Glucocorticoid signalling in fetal heart may be down-regulated by dexamethasone 
294 treatment. 
295 The decrease in MDI following dexamethasone treatment in control fetuses at E15.5, to the 
296 same level as that in SMGRKO fetal hearts, suggests that dexamethasone may have down-
297 regulated GR signalling in control fetal hearts, causing MDI (a dynamic measure) to be 
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298 equivalent to that in the GR-deficient SMGRKO hearts. Consistent with this idea, levels of 
299 Nr3c1 mRNA (encoding GR) in control fetal hearts tended to be reduced (p=0.07) following 3 
300 days dexamethasone treatment (Figure 3A). There was also a non-significant trend for 
301 down-regulation of GR protein levels in hearts of control fetuses at E15.5 following 
302 dexamethasone treatment (Supplementary Figure 3). As expected, Nr3c1 mRNA levels were 
303 lower in SMGRKO fetal hearts at E15.5 compared to control littermates and were unaffected 
304 by dexamethasone (Figure 3A). By E17.5, 2 days after cessation of dexamethasone 
305 treatment, cardiac Nr3c1 mRNA levels had largely recovered in control fetuses (Figure 3D). 
306 Levels of Fkbp5 mRNA, a glucocorticoid target gene, did not show the expected increase 
307 with dexamethasone treatment in control fetal hearts at E15.5, nor were they different in 
308 SMGRKO hearts (Figure 3B). At E17.5, Fkbp5 mRNA levels remained unaffected by prior 
309 dexamethasone treatment (Figure 3E). Similarly, Kcnj12, a direct target of GR in fetal 
310 cardiomyocytes (Rog-Zielinska et al., 2015), was down-regulated by dexamethasone in 
311 control fetuses at E15.5 (Figure 3C), with recovery of normal levels by E17.5 (Figure 3F). 
312 These data are consistent with an acute down-regulation of glucocorticoid signalling 
313 following 3 days of dexamethasone treatment. 
314
315 Fetal glucocorticoid levels are altered by dexamethasone treatment.
316 To establish that dexamethasone reached the fetal circulation and to determine effects on 
317 endogenous glucocorticoid concentrations, the level of dexamethasone and its major 
318 metabolites 6-hydroxydexamethasone and 11-dehydrodexamethasone were measured. We 
319 have previously measured corticosterone levels in the mid- and late-gestation fetal heart 
320 (Rog-Zielinska et al., 2013), in which the rise in glucocorticoid levels reflected the late-
321 gestation rise in plasma and tissue glucocorticoid levels. Because we had limited amounts of 
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322 heart tissue, we reasoned that the concentration of steroids in liver, as an important target 
323 of glucocorticoid action as well as steroid and drug metabolism, would be indicative of 
324 overall exposure. Fetal livers were pooled from each litter to obtain sufficient sample for 
325 mass spectrometry measurement of steroid concentration. The endogenous 
326 glucocorticoids, corticosterone and 11-dehydrocorticosterone (11-DHC) were 
327 simultaneously measured. At E15.5, dexamethasone was detected in the livers of treated 
328 fetuses, though at lower levels than 6-hydroxydexamethasone (Figure 4A, B). 11-
329 dehydrodexamethasone was undetectable (over a dynamic range of assay, 0-10ng). By 
330 E17.5, neither dexamethasone nor its metabolites were detectable in fetal livers, nor were 
331 they present in vehicle-treated fetuses at either time point (data not shown). Similarly, 
332 dexamethasone and 6-hydroxydexamethasone were detected in the livers of 
333 dexamethasone-treated pregnant dams at E15.5 (Supplementary Figure 4), but not at E17.5, 
334 while 11-dehydrodexamethasone was undetectable (data not shown). 
335
336 Consistent with the low glucocorticoid environment of the fetus, corticosterone levels were 
337 low in pools of fetal livers at E15.5 and were reduced by dexamethasone treatment (Figure 
338 5A). Corticosterone levels remained suppressed in dexamethasone-exposed fetuses at 
339 E17.5, 2 days after cessation of treatment (Figure 5C). In contrast, 11-dehydrocorticosterone 
340 levels were not significantly affected by dexamethasone treatment at either time point 
341 (Figure 5B, D). Corticosterone levels in the liver of the dam were much higher than in the 
342 fetus, and although hepatic corticosterone levels in the dam tended to be reduced following 
343 dexamethasone treatment, this was not statistically significant (Supplementary Figure 5). 
344 Fetal hepatic 11-dehydrocorticosterone concentrations were an order of magnitude lower 
345 than corticosterone in the dams and were reduced by dexamethasone-treatment at E15.5. 
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346 However, levels had recovered by E17.5. These data could reflect hypothalamic-pituitary-
347 adrenal (HPA) axis suppression, reducing levels of corticosterone and/or 11-
348 dehydrocorticosterone (plasma levels of 11-dehydrocorticosterone increase following HPA 
349 axis activation (Kotelevtsev et al., 1997, Harris et al., 2001, Verma et al., 2018)). 
350 Alternatively, alterations in absolute or relative activities of maternal or fetal 11-
351 hydroxysteroid dehydrogenases, which interconvert active and intrinsically inert 
352 glucocorticoids (Chapman et al., 2013), could account for the effects of dexamethasone on 
353 endogenous glucocorticoid levels. To try to distinguish between these possibilities, we 
354 carried out in situ mRNA hybridisation to measure levels of Crh mRNA in the fetal 
355 paraventricular nucleus of the hypothalamus. However, whilst the expected Crh down-
356 regulation was seen in dexamethasone-treated SMGRKO fetuses at E15.5, there was no 
357 significant effect in control fetuses at this age, nor were there any significant treatment 
358 differences between fetuses at E17.5 (Supplementary Figure 6). Thus, the reduced 
359 corticosterone levels in dexamethasone-treated fetuses may result from altered placental 
360 and/or fetal glucocorticoid metabolism and/or transport. Alternatively, they may be a 
361 consequence of changes in pituitary and/or adrenal sensitivities, which were not assessed 
362 here.
363
364 DISCUSSION
365 Contrary to our hypothesis, administration of dexamethasone from E12.5-E15.5 does not 
366 advance fetal heart maturation in mice. MPI, a marker of fetal heart maturity (Corrigan et 
367 al., 2010, Rog-Zielinska et al., 2013), was not significantly affected by antenatal 
368 dexamethasone, nor were calcium handling genes induced. Heart function was altered 
369 though. Dexamethasone transiently decreased the MDI in control fetuses, with recovery by 
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370 2 days after cessation of treatment. Other parameters of diastolic function (DT, E/A Doppler 
371 velocity ratio, IVRT) were not significantly affected by dexamethasone. There was no effect 
372 of dexamethasone on the MDI in SMGRKO fetuses. In an adult population with a high 
373 prevalence of hypertension and diabetes but free of prevalent cardiovascular disease, MDI 
374 predicted cardiovascular events (Mishra et al., 2007). In another human study, MDI was 
375 significantly associated with age and aortic root diameter (Cuspidi et al., 2011). However, 
376 the impact of an alteration in MDI during development is unknown, both in the fetus and 
377 longer-term in adulthood. Thus, whether the reduction in the MDI in dexamethasone-
378 treated control fetuses is detrimental, beneficial or simply reflects different loading 
379 conditions, is currently unclear. Diastolic function is strongly dependent on haemodynamic 
380 status and alterations in either preload or afterload affect mitral flow velocity curves 
381 (Nishimura et al., 1989a, Nishimura et al., 1989b). The U-shaped relationship between DT 
382 and cardiovascular outcomes is strengthened by normalising for the E wave velocity, 
383 thereby correcting for loading conditions in calculating the MDI (Chinali et al., 2009, Mishra 
384 et al., 2007). Here, DT itself was unaffected by dexamethasone. This suggests that the effect 
385 of dexamethasone on the MDI in control fetuses is likely due to alterations in loading, 
386 possibly through the well-known increase in fetal blood pressure following antenatal 
387 corticosteroid administration (Derks et al., 1997, Bennet et al., 1999). In the surviving 
388 dexamethasone-treated control fetuses, MDI was normalised by E17.5. Although diastolic 
389 dysfunction in human fetuses with cardiomyopathy is associated with an 8-fold increased 
390 risk of fetal mortality compared to systolic dysfunction (Pedra et al., 2002), it is unlikely that 
391 any diastolic dysfunction reflected in the lower MDI at E15.5 contributes to the reduced 
392 fetal survival at E17.5. Dexamethasone treatment has a similar effect in reducing the 
393 number of SMGRKO and control fetuses at E17.5, yet the MDI in SMGRKO mice is 
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394 unaffected by dexamethasone. Nevertheless, it is possible that systemic factors, particularly 
395 haemodynamic, differentially affect diastolic function in SMGRKO and control fetuses. The 
396 increase in wet weight at E17.5 in SMGRKO fetuses with prior dexamethasone treatment is 
397 consistent with our previous finding of mild oedema in untreated SMGRKO fetuses at E17.5 
398 (Rog-Zielinska et al., 2013) and suggests genotype-specific cardiac and/or haemodynamic 
399 effects of dexamethasone. Whether dexamethasone causes or exacerbates oedema in 
400 SMGRKO fetuses requires experimental confirmation. SMGRKO mice have normal blood 
401 pressure as adults (Richardson et al., 2017). However, in an independent line of mice with 
402 GR deletion in VSMC (as in our SMGRKO mice) dexamethasone-induced hypertension is 
403 attenuated in adulthood (Goodwin et al., 2008). Whether GR action in VSMC contributes to 
404 the fetal heart phenotype observed here remains to be established. 
405
406 The lack of difference in MPI between genotypes and with dexamethasone treatment, was 
407 surprising, as was the lack of genotype difference in calcium handling gene expression, at 
408 least at E17.5. We have previously described an increase in MPI at E17.5 in SMGRKO fetuses 
409 compared with controls, and SMGRKO fetuses have lower cardiac expression of Atp2a2 and 
410 Ryr2 than littermate controls at E17.5 (Rog-Zielinska et al., 2013). The reason we failed to 
411 see those differences here is unclear; a reduction in cardiac GR expression in SMGRKO mice 
412 was confirmed. However, the SMGRKO mice used here have undergone several generations 
413 of breeding since the original line was generated and characterised, and it is possible that 
414 compensatory genetic changes have occurred (e.g. due to selection of surviving Cre+ male 
415 mice from which to breed), accounting for these findings. It is also possible that the 
416 difference in experimental conditions (e.g. daily weighing of the mice or factors unknown to 
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417 us that alter haemodynamic status) could account for the discrepancies between this and 
418 our previous study. Ongoing and future studies will investigate this.  
419
420 Nevertheless, a genotype-specific impact of dexamethasone upon the fetus is evident in this 
421 study. Our steroid measurements confirm dexamethasone in fetal livers, albeit at a 
422 concentration ~10-fold lower than in the maternal liver. This is consistent with previous 
423 reports of a gradient of this magnitude between maternal and fetal serum in the late 
424 gestation rat (Varma, 1986). Interestingly, levels of 6-hydroxydexamethasone, an active 
425 metabolite of dexamethasone (Ritchie et al., 1992), are at least as high in the fetal liver as in 
426 the maternal liver. This relatively high level of 6-hydroxydexamethasone in the fetal liver 
427 suggests metabolism of dexamethasone to 6-hydroxydexamethasone by the feto-placental 
428 unit. This is the first known example of evidence for 6-hydroxydexamethasone expression in 
429 the mouse fetal liver.
430
431 Because, at E15.5, dexamethasone had no effect on the MDI in SMGRKO fetuses, but 
432 decreased the MDI in control fetuses (to be the same as in SMGRKO), we hypothesised that 
433 GR was down-regulated in cardiomyocytes and/or VSMC of control mice after the 3 days of 
434 dexamethasone treatment. Down-regulation of GR in response to dexamethasone 
435 treatment is well known (Wilkinson et al., 2018) and lower GR expression in the heart of 
436 control animals may explain the lack of dexamethasone effect on Fkbp5, a well-known GR 
437 target gene as well as Kcnj12, a GR target in cardiomyocytes (Rog-Zielinska et al., 2015). Any 
438 reduction in glucocorticoid sensitivity due to reduced GR expression is transient, recovering 
439 2 days after termination of dexamethasone administration. Genes involved in calcium 
440 handling are normally induced following GR activation in cardiomyocytes, albeit by indirect 
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441 mechanisms. The transient decrease at E15.5 with recovery by E17.5 is also consistent with 
442 down-regulation of GR. However, the decrease in GR that impacts calcium handling is likely 
443 not in cardiomyocytes/VSMC, as calcium handling was also affected by dexamethasone in 
444 SMGRKO mice. The locus of this regulation of cardiac gene expression by dexamethasone is 
445 currently unclear. Dexamethasone treatment also perturbs endogenous fetal glucocorticoid 
446 levels, and the effect on the HPA axis appears complex. Prolonged suppression of the fetal 
447 HPA axis is suggested by the decrease in fetal corticosterone concentration without a 
448 significant change in 11-dehydrocorticosterone following dexamethasone treatment to 
449 E15.5 and persisting 2 days after cessation of treatment at E17.5. Whether or not this 
450 suppression of the fetal HPA axis persists beyond E17.5 was not investigated here, though 
451 antenatal glucocorticoid exposure is known to exert long-term programming effects upon 
452 HPA axis activity (Agnew et al., 2018, Rog-Zielinska et al., 2014). Contrary to expectations, 
453 Crh mRNA was not down-regulated by dexamethasone in control animals, though it was in 
454 SMGRKO fetuses at E15.5, with recovery observed by E17.5. Because, for methodological 
455 reasons, fetal livers from both genotypes were pooled for steroid measurements, we could 
456 not determine whether hepatic corticosterone levels in the SMGRKO and control livers were 
457 similarly affected by dexamethasone treatment. Thus, it remains possible that there is a 
458 differential effect of dexamethasone upon fetal corticosterone levels in SMGRKO and 
459 control fetuses, as well as upon the HPA axis. Whilst speculative, this naturally raises the 
460 question of how HPA axis suppression could arise in SMGRKO but not control fetuses. It has 
461 been suggested that resistance to negative feedback by glucocorticoids is essential to allow 
462 the late gestation increase in glucocorticoid levels (Matthews and Challis, 1996). CRH is not 
463 suppressed by antenatal betamethasone treatment in the late gestation sheep fetus, 
464 despite reduced cortisol levels (Li et al., 2013). In contrast, in the late gestation guinea pig 
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465 fetus, CRH expression is reduced by repeated injection of synthetic glucocorticoids, 
466 demonstrating sensitivity to negative feedback (McCabe et al., 2001). Interestingly, in the 
467 late gestation fetal sheep hypothalamus, basal CRH synthesis is resistant to 
468 hypercortisolaemia, whereas increased CRH synthesis in response to hypoxia is highly 
469 sensitive to glucocorticoid negative feedback (Matthews and Challis, 1995b, Matthews and 
470 Challis, 1995a). Whether such a mechanism operates in mice requires investigation. CRH 
471 synthesis is sensitive to haemodynamic variation in the fetus (Ng, 2000), and conceivably, 
472 may be differentially regulated in SMGRKO and control fetuses, if haemodynamic forces 
473 differ between the genotypes in response to dexamethasone. It is also possible that sex 
474 differences may account for some of the differential effects. For example, the HPA axis of 
475 male guinea pig fetuses is more sensitive to negative feedback by maternally administered 
476 glucocorticoids at the pituitary level than that of the female fetuses (Owen et al., 2005). 
477 Males and females were not distinguished here.
478
479 Dexamethasone reduces survival of both SMGRKO and control fetuses at E17.5 (2 days after 
480 cessation of dexamethasone treatment). The cause of death is currently unknown, but 
481 plausibly could relate to reduced capacity for calcium handling, which was affected in both 
482 genotypes. It is possible that the dexamethasone-related deaths have biased our findings at 
483 E17.5, if deaths occurred in more severely impacted fetuses; indeed, a limitation of the 
484 current study is that data from all fetuses were included, irrespective of litter size. Thus, the 
485 analysis could possibly have been subject to maternal bias. Of note, in a large clinical study 
486 in low and mid-income countries, antenatal dexamethasone treatment increased the 
487 incidence of neonatal death (Althabe et al., 2015). The risk was greatest in those babies 
488 born close to term and importantly, only 16% of the women who recieved antenatal 
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489 corticosteroid actually went on to deliver their baby preterm. This raises concerns about 
490 possible harmful effects of non-optimally administered antenatal corticosteroids. Our study 
491 is consistent with these clinical data and suggest cessation of glucocorticoid treatment 
492 confers an increased vulnerability to sudden death. Whilst undoubtedly life saving when 
493 appropriately administered, many women administered antenatal corticosteroids in high 
494 income countries do not deliver their babies within 1-7 days following treatment (reviewed, 
495 Kemp et al., 2017). This highlights a need for further research to fully understand the 
496 consequences of antenatal glucocorticoid administration, to inform and refine antenatal 
497 corticosteroid therapy.
498 In sheep, late gestation maternal hypercortisolemia causes perinatal death (Keller-Wood et 
499 al., 2014), associated with cardiac arrhythmias and decreased fetal aortic pressure (Antolic 
500 et al., 2018). Thus, there appears an inverted U-shaped relationship between glucocorticoid 
501 levels and fetal survival with both glucocorticoid deficiency and glucocorticoid excess 
502 reducing perinatal survival. At least some of this effect is likely to be mediated by the 
503 complex effects of glucocorticoids on haemodynamic parameters and cardiac function 
504 described by us (Richardson et al., 2017, Gray et al., 2016, Rog-Zielinska et al., 2013), and by 
505 others (Richards et al., 2014, Reini et al., 2008, Feng et al., 2013, Antolic et al., 2018, Oakley 
506 et al., 2013). Unravelling these complex relationships, and the impact of genetic variation in 
507 glucocorticoid signalling upon fetal haemodynamic function, will be important for future 
508 therapy in preterm birth and in managing the consequences of extreme maternal stress.  
509 Effects on placental function were not investigated here. However, placental vascularisation 
510 and haemodynamic forces are critical regulators of cardiac maturation (Burton et al., 2016, 
511 Thornburg et al., 2010, Morrison et al., 2007). Moreover, recent data in Hsd11b2-/- mice 
512 suggest pharmacological rescue of impaired placental vasculature also rescues normal fetal 
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513 cardiac maturation (Wyrwoll et al., 2016). Future research should address the impact of 
514 synthetic glucocorticoid administration upon placental vasculature and haemodynamics, in 
515 conjunction with effects on heart. 
516 The long-term consequences of the dexamethasone treatment utilised here were not 
517 examined. However, in humans and in animals there is an association between excessive 
518 glucocorticoid exposure in utero and an increased risk of cardiovascular disease in adult 
519 offspring (reviewed, (Rog-Zielinska et al., 2014, Agnew et al., 2018)). There are relatively few 
520 studies of the effects of antenatal glucocorticoid treatment upon adult cardiovascular 
521 disease risk in mice. A previous study in which mice were administered dexamethasone 
522 from E12.5 to E15 reported growth restriction and a trend for decreased heart weight at 
523 E14.5, with catch up by E17.5. As adults, the dexamethasone-exposed mice had normal 
524 hearts, but increased blood pressure and pulse pressure compared to controls (O'Sullivan et 
525 al., 2013). Mice are born relatively immature compared to humans. However, the scant 
526 evidence available suggests that early postnatal cardiomyocyte maturation, including 
527 capacity for proliferation and heart repair, is similar in mice and humans. In both humans 
528 and mice there is a period in which cardiomyocytes continue to proliferate after birth (albeit 
529 possibly over a longer period in humans than the 1 week postnatally in mice) (Porrello et al., 
530 2011, Mollova et al., 2013, Bergmann et al., 2015, Haubner et al., 2015, Yutzey, 2017). 
531 Whether mid to late gestation cardiomyocyte maturation is similar in humans and mice is 
532 currently unknown. Our data, however, suggest that even transient effects of antenatal 
533 dexamethasone can interfere with the normal trajectory of cardiac maturation, possibly 
534 through altered haemodynamics, known to be affected by antenatal dexamethasone in 
535 humans (Mulder et al., 2009), thus potentially impacting on adult cardiovascular health. 
536 Thus, whilst antenatal glucocorticoids are undoubtedly of clinical benefit in infants born 
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537 preterm, there may be detrimental effects on the heart and other organs, as seen here in an 
538 animal model. Future studies should establish the short as well as long-term effects of 
539 antenatal corticosteroid therapy on human heart. The benefit versus risk balance must be 
540 carefully considered by clinicians before administering antenatal glucocorticoids. Further 
541 research is needed to optimize the timing and dosage to provide the most beneficial 
542 outcome overall.
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11 FIGURE LEGENDS
2
3 Figure 1: Dexamethasone treatment reduces fetal number and litter size at E17.5 without 
4 affecting either at E15.5. 
5 Dexamethasone (Dex, stippled bars: 100µg/kg/day) or vehicle (Veh, white bars) was 
6 administered to pregnant dams in their drinking water from E12.5 to E15.5. Individual data 
7 points represent mean values per litter. Data are means ± SEM and were analysed by 
8 Student’s t-test (A, C) or 2-way ANOVA with post-hoc Tukey tests (B, D). Significant effect of 
9 treatment, *p<0.05, **p<0.01; significant effect of genotype, #p<0.05, n=12-13 litters per 
10 group.
11
12 Figure 2: Dexamethasone transiently reduces the mitral deceleration index, dependent on 
13 GR. 
14 Dexamethasone (100µg/kg/day; stippled bars) or vehicle (Veh, white bars) was 
15 administered to pregnant dams from E12.5 to E15.5. Mitral deceleration index (MDI) was 
16 measured by in vivo ultrasound imaging at (A) E15.5 and (B) E17.5. Data are means ± SEM 
17 and were analysed by 2-way ANOVA with post-hoc Tukey tests: significant effect of 
18 treatment, *p<0.05; significant effect of genotype, #p<0.05, n=8-28 fetuses from 5-6 litters 
19 per group.
20
21 Figure 3: Glucocorticoid signalling in hearts of control fetuses is down-regulated by 
22 dexamethasone at E15.5. 
23 Dexamethasone (100µg/kg/day, stippled bars) or vehicle (Veh, white bars) was 
24 administered to pregnant dams in their drinking water from E12.5 to E15.5. qRT-PCR 
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225 measurements at E15.5 of cardiac levels of (A) Nr3c1 mRNA, (B) Fkpb5 mRNA, (C) Kcnj12 
26 mRNA, all relative to the mean of Actb, Hprt and Tbp mRNA levels, and at E17.5 of (D) Nr3c1 
27 mRNA, (E) Fkbp5 mRNA and (F) Kcnj12 mRNA, all relative to the mean of 18s, Hprt and Tbp 
28 mRNA levels. Data, in arbitrary units (A.U.), are means ± SEM and were analysed by 2-way 
29 ANOVA with post-hoc Tukey tests (###p<0.001, ##p<0.01, #p<0.05 vs vehicle-treated 
30 control mice), n=7-17 fetuses from 6 litters per group.
31
32 Figure 4: Dexamethasone and its metabolite 6-hydroxydexamethasone are present in 
33 livers of dexamethasone-treated fetuses at E15.5. 
34 Dexamethasone (Dex, stippled bars: 100µg/kg/day) or vehicle (Veh, white bars) was 
35 administered to pregnant dams from E12.5 to E15.5, with no further treatment to E17.5. 
36 Dexamethasone (A) and 6-hydroxydexamethasone (B) were measured in fetal livers pooled 
37 from each litter (approximately 100mg tissue), by mass spectrometry. The detectable range 
38 for dexamethasone was 0.01-5ng and for 6-hydroxydexamethasone 0.5-25ng. Values are 
39 expressed as ng steroid/g fetal liver. Each data point represents a single pool of fetal livers 
40 from one litter. Data are means ± SEM and were analysed by unpaired Student’s t-test 
41 (**p<0.01, ***p<0.001), n=4-6.
42
43 Figure 5: Suppression of corticosterone levels in fetal liver following dexamethasone 
44 treatment. 
45 Dexamethasone (Dex, stippled bars: 100µg/kg/day) or vehicle (Veh, white bars) was 
46 administered to pregnant dams from E12.5 to E15.5, with no further treatment to E17.5. 
47 Steroids were measured in fetal livers pooled from each litter (approximately 100mg tissue), 
48 by mass spectrometry. The upper and lower limits of detection of both corticosterone and 
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349 11-dehydrocorticosterone (11-DHC) was 0.05-10ng. Levels of (A) corticosterone at E15.5, (B) 
50 11-DHC at E15.5, (C) corticosterone at E17.5 and (D) 11-DHC at E17.5. Values are expressed 
51 as ng steroid/g fetal liver with each data point representing a single pool of fetal livers from 
52 one litter. Data are means ± SEM and were analysed by unpaired Student’s t-test; **p<0.01, 
53 n=4-6.
54
55 SUPPLEMENTARY FIGURE LEGENDS
56
57 Supplementary Figure 1. No association between mean fetal weight per litter and litter size, in 
58 vehicle and dexamethasone treated mice.
59 Dexamethasone (Dex: 100µg/kg/day) or vehicle (Veh) was administered from E12.5 to E15.5. 
60 Individual data points represent mean fetal weight per litter (g). R2 values were as follows, (A) E15.5 
61 vehicle: 0.127, (B) E15.5 dexamethasone: 0.041, (C) E17.5 vehicle: 0.01, (D) E17.5 dexamethasone: 
62 0.009. n=10-12 litters.
63
64 Supplementary Figure 2. Levels of mRNA encoding calcium handing proteins are altered at E15.5 by 
65 dexamethasone treatment. Dexamethasone (100µg/kg/day, stippled bars) or vehicle (Veh, white 
66 bars) was administered to pregnant dams in their drinking water from E12.5 to E15.5. qRT-PCR 
67 measurements at (A) E15.5 and (B) E17.5 of cardiac levels of (left to right, respectively) Ryr2 mRNA 
68 (encoding RYR2), Atp2a2 mRNA (encoding SERCA2a), Slc8a1 mRNA (encoding NCX1) and Cacna1c 
69 mRNA (encoding Cav1.2). E15.5 measurements are relative to the mean of Actb, Hprt and Tbp mRNA 
70 levels and E17.5 are relative to the mean of 18s, Hprt and Tbp mRNA levels. Data, in arbitrary units 
71 (A.U.), are means ± SEM and were analysed by 2-way ANOVA with post-hoc Tukey tests. At E15.5, 
72 ANOVA showed a borderline significant genotype effect (p=0.054) for Ryr2, and significant effects of 
73 treatment for Atp2a2 (p<0.05), Slc8a1 (p<0.01) and Cacna1c (p<0.001). At E17.5, ANOVA showed a 
74 significant effect of treatment for Cacna1c (p<0.01). Post-hoc tests: ##p<0.01, #p<0.05,  n=7-17 
75 fetuses from 6 litters per group .
76
77 Supplementary Figure 3. GR protein levels in control fetal hearts at E15.5. 
78 Western blotting (representative image in upper panel) was used to measure protein levels in hearts 
79 of vehicle (V/Veh) and dexamethasone (D/Dex) treated mice. Graph shows quantification of GR 
80 protein levels relative to β-tubulin. Data are means ± SEM and were analysed by unpaired Student’s 
81 t-test, n= 4 (number of fetuses, from n=2-4 litters per group).
82
83 Supplementary Figure 4. Dexamethasone and its 6-hydroxydexamethasone metabolite are present 
84 in livers of dexamethasone-treated dams at E15.5. 
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485 Dexamethasone (Dex: 100µg/kg/day) or vehicle (Veh) was administered from E12.5 to E15.5. 
86 Steroids were measured in maternal livers by mass spectrometry. The detectable range for (A) 
87 dexamethasone was 0.5-50ng, and for (B) 6-hydroxydexamethasone 0.1-5ng. Values are expressed 
88 as ng steroid/g liver. Data are means ± SEM and were analysed by unpaired Student’s t-test 
89 (*p<0.05, **p<0.01). Each data point represents a single dam, n=4-6.
90
91 Supplementary Figure 5. Endogenous glucocorticoid levels in dam liver at E15.5 and E17.5. 
92 Dexamethasone (Dex: 100µg/kg/day) or vehicle (Veh) was administered from E12.5 to E15.5. Steroid 
93 levels were measured in maternal livers by mass spectrometry: (A) corticosterone at E15.5, (B) 11-
94 dehydrocorticosterone (11-DHC) at E15.5, (C) corticosterone at E17.5 and (D) 11-DHC at E17.5 . For 
95 E15.5 samples, the detectable range for corticosterone was 0.025-50ng and 11-DHC, 0.1-50ng. For 
96 E17.5 samples, the detectable range for corticosterone was 0.0025-10ng and 11-DHC, 0.0025-50ng. 
97 Values are expressed as ng steroid/g liver.  Data are means ± SEM and were analysed by unpaired 
98 Student’s t-test,***p<0.001. Each data point represents a single dam, n=4-6.
99
100 Supplementary Figure 6. SMGRKO fetal HPA axis is downregulated at E15.5 following dex exposure, 
101 with no change at E17.5 or in the control ‘floxed’ group. Corticotropin releasing hormone (Crh) 
102 mRNA levels were measured bilaterally in the PVN of the hypothalamus by in situ hybridisation. (A) 
103 Representative images of autoradiographs of sections of fetal brain showing hybridisation of Crh 
104 mRNA in E15.5 (top panels) and E17.5 (bottom panels) control (left two panels) and SMGRKO (right 2 
105 panels) fetal brains. Fetuses were vehicle or dexamethasone exposed, as indicated. (B, C) 
106 Densitometric quantification of Crh mRNA at (B) E15.5 and (C) E17.5. Levels of mRNA are expressed 
107 in arbitrary units (A.U.) with vehicle treated control set to 1. Data are means ± SEM and were 
108 analysed by 2-way ANOVA with post-hoc Tukey tests. (B) There was no significant effect of genotype 
109 or dexamethasone treatment individually, but there was a significant interaction (p=0.040). (C) Two-
110 way ANOVA showed a significant effect (p=0.037) effect of genotype. n= 5-13 (number of fetuses, 
111 from n=2-5 litters per group).
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TABLE 1: Dexamethasone treatment increased body weight of SMGRKO fetuses at 
E17.5 but had no effect on fetal body weight or heart weight at E15.5.
Dexamethasone (100µg/kg/day) or vehicle was administered to pregnant dams in 
drinking water, from E12.5 to E15.5. Fetuses were collected at E15.5 or E17.5. Fetal 
body and heart weights are in mg with heart weight also expressed relative to body 
weight. Data are means ± SEM and were analysed using 2-way ANOVA with post-hoc 
Tukey’s test; **p<0.01 vs untreated SMGRKO, †p<0.05 vs dexamethasone-treated 
controls. Body weight: n= 29-52 fetuses from 5-12 litters/treatment). Heart weight: 
n=11-28 fetuses from 5-6 litters/treatment).
E15.5     
Vehicle Dexamethasone
Control SMGRKO Control SMGRKO
Body weight (mg) 420.7  20.1 435.6  18.0 459.0  14.6 428.6  14.9
Heart weight (mg) 12.4  1.0 12.8  0.7 13.7  0.7 14.0  0.9
Heart weight/
body weight 
0.034  0.003 0.035  0.002 0.036  0.003 0.035  0.003
E17.5
Body weight (mg) 873.9  14.3 850.8  13.4 855.2  22.0 954.5  36.4**, †
Heart weight (mg) 13.1  0.7 13.2  0.7 13.8  0.5 14.3  0.12
Heart weight/
body weight
0.015  0.001 0.016  0.001 0.017  0.001 0.018  0.002
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1 Supplementary Table 1. Primer sequences and the corresponding probes used for qRT-PCR analysis of mRNA.2 Sequences of forward and reverse primers and the Universal Probe Library probe number used in qRT-PCR assays to measure levels of specific 3 mRNAs. 4
mRNA Sequence 5’-3’ Probe
Forward Reverse
Actb CTAAGGCCAACCGTGAAAAG ACCAGAGGCATACAGGGACA 64
Atp2a2 TCGACCAGTCAATTCTTACAGG CAGGGACAGGGTCAGTATGC 94
Cacna1c CCTGCACAAGGGCTCTTTC AGATGAGGGACACGCTAACC 62
Fkbp5 AAACGAAGGAGCAACGGTAA TCAAATGTCCTTCCACCACA 97
Hprt TCCTCCTCAGACCGCTTTT CCTGGTTCATCATCGCTAATC 95
Kcnj12 GGCCTAGACCGTATCTTCCTG TGGCCTCATCAATCTCGTG 9
Nr3c1 CAAAGATTGCAGGTATCCTATGAA CTTGGCTCTTCAGACCTTCC 91
Ryr2 TTCAACACGCTCACGGAGTA TGCCAGGCTCTGCTGATT 81
Slc8a1 GTCAGCCTTCAGAGCTGGTC GACTTCCAACTGCTCCAACC 42
Tbp GGGAGAATCATGGACCAGAA GATGGGAATTCCAGGAGTCA 9756
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Supplementary Table 2. Echocardiography parameters measured in E15.5 and E17.5 fetal mice. 
Pregnant dams were administered dexamethasone (Dex, 100µg/kg/day) or vehicle (Veh) in their drinking water from E12.5 to E15.5. Fetal 
cardiac function was assessed at E15.5 or E17.5 using a Visualsonics Vevo 770 High Resolution Ultrasound Scanner using Doppler mode. IVCT: 
isovolumetric contraction time, IVRT: isovolumetric relaxation time, ET: ejection time, MPI: myocardial performance index, calculated as 
(IVCT+IVRT)/ET, HR: heart rate measured as beats per minute (bpm), E/A: E/A wave ratio, DT: deceleration time. Data are means ± SEM and 
were analysed by 2-way ANOVA, with post-hoc Bonferroni tests. P values are stated where p=0.1 to 0.05. Significantly different compared to 
same treatment and genotype at E15.5, p<0.05, p<0.001, n=7-29 fetuses, from 5-6 litters per group.
E15.5
Veh Dex ANOVA
Parameter Control (n=15) SMGRKO (n=24) Control (n=14) SMGRKO (n=28) Treatment Genotype Interaction
IVCT (ms) 27.36  1.62 27.97  1.11 32.71  2.14 29.09  1.77 p=0.068 NS NS
IVRT (ms) 40.92  1.48 42.66  1.33 41.43  1.15 40.67  1.09 NS NS NS
ET (ms) 109.44  4.44 106.60  2.41 114.08  2.86 106.22  2.65 NS p=0.090 NS
MPI 0.64  0.04 0.66  0.02 0.65  0.03 0.66  0.03 NS NS NS
E/A 0.33  0.03 0.34  0.02 0.36  0.02 0.32  0.02 NS NS NS
DT (ms) 56.34  3.68 48.87  2.91 61.99  5.17 53.97  3.52 NS p=0.054 NS
HR (bpm) 211.1  6.6 216.7  4.3 198.9  6.9 214.4  5.9 NS p=0.092 NS
E17.5
Veh Dex ANOVA
Control (n=18) SMGRKO (n=23) Control (n=8) SMGRKO (n=20) Treatment Genotype Interaction
IVCT (ms) 29.58  1.91 31.09  2.03 26.62  1.92 29.43  1.26 NS NS NS
IVRT (ms) 35.59  0.98 33.90  0.85 36.77  1.06 33.94  1.06 NS p<0.05 NS
ET (ms) 99.20  2.06 104.31  2.20 102.45  2.86 99.02  2.03 NS NS p=0.091
MPI 0.68  0.03 0.61  0.02 0.63  0.04 0.61  0.02 NS NS NS
E/A 0.47  0.03 0.46  0.02 0.45  0.02 0.42  0.02 NS NS NS
DT (ms) 46.35  2.31 44.28  2.37 49.35  3.15 44.85  2.94 NS NS NS
HR (bpm) 223.52  6.47 224.16  5.37 215.38  8.87 231.38  6.54 NS NS NS
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